Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Kaur, Sukhwinder ^a   Chakraborty, Subhankar ^a   Baine, Michael J ^b   Mallya, Kavita ^a   Smith, Lynette M ^b   Sasson, Aaron ^a   Brand, Randall ^c   Guha, Sushovan ^d   Jain, Maneesh ^a   Wittel, Uwe ^e   Singh, Shailender K ^a   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; GROWTH DIFFERENTIATION FACTOR 15; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ACUTE-PHASE PROTEINS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY MASS INDEX; CA-19-9 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; LIPOCALINS; LOGISTIC MODELS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROTO-ONCOGENE PROTEINS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84873246972     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055171     Document Type: Article

References (25)

1. Chakraborty S, Baine MJ, Sasson AR, Batra SK, (2011) Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 1815: 44-64.
2. Torigian DA, Huang SS, Houseni M, Alavi A, (2007) Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 57: 206-224.
3. Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, et al. (2008) Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 98: 1540-1547.
4. El-Mesallamy HO, Hamdy NM, Zaghloul AS, Sallam AM (2012) Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic Cancer Diagnosis. Pancreas (In Press).
5. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, et al. (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94: 11514-11519.
6. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, et al. (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10: 2386-2392.
7. Ozkan H, Demirbas S, Ibis M, Akbal E, Koklu S, (2011) Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases. Pancreatology 11: 295-300.
8. Misek DE, Patwa TH, Lubman DM, Simeone DM, (2007) Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw 5: 1034-1041.
9. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, et al. (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12: 442-446.
10. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, et al. (1983) Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29: 549-552.
11. Nairz M, Theurl I, Schroll A, Theurl M, Fritsche G, et al. (2009) Absence of functional Hfe protects mice from invasive Salmonella enterica serovar Typhimurium infection via induction of lipocalin-2. Blood 114: 3642-3651.
12. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, et al. (2004) Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432: 917-921.
13. Chakraborty S, Kaur S, Guha S, Batra SK, (2012) The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826: 129-169.
14. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, et al. (2008) Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 68: 6100-6108.
15. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, et al. (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66: 4983-4986.
16. Hustinx SR, Cao D, Maitra A, Sato N, Martin ST, et al. (2004) Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 3: 1254-1261.
17. Duffy MJ, (1998) CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 35 (Pt 3): 364-370.
18. Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, et al. (2009) CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 28: 24-27.
19. Buxbaum JL, Eloubeidi MA, (2010) Molecular and clinical markers of pancreas cancer. JOP 11: 536-544.
20. Morris-Stiff G, Teli M, Jardine N, Puntis MC, (2009) CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 8: 620-626.
21. Cho H, Kim JH, (2009) Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem 57: 513-521.
22. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, et al. (2008) Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 108: 389-397.
23. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, et al. (2007) Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 53: 34-41.
24. Skipworth RJ, Deans DA, Tan BH, Sangster K, Paterson-Brown S, et al. (2010) Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br J Cancer 102: 665-672.
25. Shnaper S, Desbaillets I, Brown DA, Murat A, Migliavacca E, et al. (2009) Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer 125: 2624-2630.